XTLB XTL Biopharmaceuticals Ltd. - American Depositary Shares
XTLB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
XTLB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| XTLB | — | — | — | — | — | — |
| ENLV | — | — | — | — | — | — |
| PLRZ | — | — | — | — | — | — |
| PLUR | $39M | -1.4 | 309.8% | -1690.3% | 669.5% | 48.9% |
| CMMB | — | — | — | — | — | — |
| NRSN | — | — | — | — | — | — |
| QNRX | $757M | — | — | — | -201.7% | — |
| EVGN | — | — | — | — | — | — |
| URGN | $1.13B | — | 21.4% | -139.8% | 154.4% | 88.7% |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F)
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 3 (+3 vs prior Q) | 1 (+1 vs prior Q) | 1 (+1 vs prior Q) | 1 (-1 vs prior Q) | +103K |
Compared to Q3 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
Company insiders 3 insiders · 1 officers · 2 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ron Bentsur | CEO | Aug. 21, 2007 P | 20,101 | 0 | 0 | $0 |
| Ben-Zion Weiner | Director | Oct. 10, 2008 A | — | 0 | 0 | $0 |
| Michael S Weiss | Director | Dec. 30, 2007 G | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Undisclosed reporting person, Undisclosed reporting person | Dec. 3, 2008 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | July 18, 2008 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | July 17, 2008 | — | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.